683 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

683 Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71,500	Closed	-$2.28M	–	143
2024 Q4	$2.28M	Sell	71,500 -128,500	-64%	-$3.86M	0.14%	86
2024 Q3	$5.77M	Hold	200,000	–	–	0.44%	58
2024 Q2	$7.67M	Buy	+200,000	New	+$9.06M	0.58%	47
2024 Q1	–	Sell	-175,000	Closed	-$10.5M	–	148
2023 Q4	$10.5M	Sell	175,000 -401,000	-70%	-$20.3M	0.86%	46
2023 Q3	$21.9M	Buy	576,000 +75,000	+15%	+$3.29M	1.7%	17
2023 Q2	$45.6M	Buy	+501,000	New	+$43.2M	3.28%	6

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

683 Capital Management's APLS Position: Q2 2026 in Review

683 Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 250,000 shares — an estimated $10.1M sold.

683 Capital Management first reported a position in APLS in Q4 2022 and held it in 14 quarters. The position peaked at $12.6M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

683 Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 250,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.1M.
683 Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 14 quarters.
683 Capital Management's Apellis Pharmaceuticals position peaked at $12.6M in Q1 2024.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.